The HWP Group (HWP), a leading medical communications and strategic consulting partner to the life sciences industry, has announced the acquisition of Global Market Access Solutions (GMAS), a highly regarded market access and health economics consultancy with global operations.
With the addition of GMAS, HWP expands its capabilities in market access strategy, health economics and outcomes research (HEOR), pricing and payer insights, evidence synthesis and life cycle value strategy.
The combined organization is uniquely positioned to support clients across the entire product life cycle from early clinical development through launch, reimbursement and sustained patient access.
“With this acquisition, HWP takes a decisive step forward in our mission to help clients bridge the gap between scientific innovation and real‑world patient access,” said Jani Hegarty, chief executive officer and founder of The HWP Group.
“Market access and health economics are no longer optional — they are foundational. By integrating GMAS’ capabilities into HWP, we can now help clients not only tell a compelling scientific story but also prove economic value to payers and health systems — ensuring faster, broader and more sustainable patient access.”
“Nikos Kotsopoulos, Ph.D., and I are thrilled to join The HWP Group and continue our efforts to improve patient access to medications,” said GMAS managing partner Mark Connolly, Ph.D.
“This change allows us to scale our market access and HEOR expertise within a platform that shares our commitment to rigor, strategy, and partnership.
“Together, we are exceptionally well-positioned to help life sciences companies ensure their innovations are not only approved but reimbursed, accessible and impactful.”
This acquisition further solidifies the position of HWP as a full‑service strategic partner to pharmaceutical and biotechnology companies navigating increasingly complex global markets, where clinical excellence must be matched by compelling economic evidence to achieve reimbursement, market adoption and meaningful patient impact.
